Pure Global AI
NCT06059326Completed

Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM

A Multicenter, Randomized, Double-blind, Placebo Control, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in Type 2 Diabetes Mellitus Patients
Haisco Pharmaceutical Group Co., Ltd.Phase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Type 2 Diabetes Mellitus
Drug/Device/Intervention
HSK7653 10 mg
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Haisco Pharmaceutical Group Co., Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 2
Start date
Jan 22, 2019
End date
Nov 05, 2019
Enrollment
48 participants
Primary outcome

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

Summary

To evaluate the safety, tolerability and pharmacokinetic (PK)/pharmacodynamic (PD)
 characteristics of HSK7653 tablets in Type 2 Diabetes Mellitus Patients.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06059326
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06059326 through Pure Global AI's free database. This Phase 2 trial is sponsored by Haisco Pharmaceutical Group Co., Ltd. and is currently Completed. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.